Cost effectiveness in the treatment of advanced solid tumours
When the treatment of advanced cancer is palliative in intent, evaluation of quality of life is of paramount importance in judging the effectiveness of treatment. The balance between adverse effects (costs) and benefits has been particularly difficult to determine with cytotoxic drugs. An approach t...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 1993, Vol.29 (4), p.604-605 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 605 |
|---|---|
| container_issue | 4 |
| container_start_page | 604 |
| container_title | European journal of cancer (1990) |
| container_volume | 29 |
| creator | Rubens, R.D. |
| description | When the treatment of advanced cancer is palliative in intent, evaluation of quality of life is of paramount importance in judging the effectiveness of treatment. The balance between adverse effects (costs) and benefits has been particularly difficult to determine with cytotoxic drugs. An approach to this problem using medical audit is described. It has been found to be a reliable method which has demonstrated a highly significant correlation between achievement of objective regression and acquisition of benefit. The method is now undergoing corroboration by a prospective study. |
| doi_str_mv | 10.1016/S0959-8049(05)80162-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75575774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804905801625</els_id><sourcerecordid>75575774</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-f13a15239cbe87a9dc9dea67cfa1902ab421434fc768e7e72d4bab911cf9d4983</originalsourceid><addsrcrecordid>eNqFkEtLAzEUhYMotVZ_QmFWoovRZCaZJAsRKb6g4EJdh0xyg5F51CRT8N87fdCtqwv3nHMP90NoTvANwaS6fceSyVxgKq8wuxbjqsjZEZoSwWWOBSuO0fRgOUVnMX5jjLmgeIImvOKSiWKK7hZ9TBk4Byb5NXQQY-a7LH1BlgLo1EKXst5l2q51Z8BmsW-8zdLQ9kOI5-jE6SbCxX7O0OfT48fiJV--Pb8uHpa5KSucckdKTVhRSlOD4FpaIy3oihunicSFrmlBaEmd4ZUADrywtNa1JMQ4aakU5Qxd7u6uQv8zQEyq9dFA0-gO-iEqzhhnnNPRyHZGE_oYAzi1Cr7V4VcRrDbY1Bab2jBRmKktNsXG3HxfMNQt2ENqz2nU73c6jF-uPQQVjYcNEB9Gcsr2_p-GP5hdfRk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75575774</pqid></control><display><type>article</type><title>Cost effectiveness in the treatment of advanced solid tumours</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rubens, R.D.</creator><creatorcontrib>Rubens, R.D.</creatorcontrib><description>When the treatment of advanced cancer is palliative in intent, evaluation of quality of life is of paramount importance in judging the effectiveness of treatment. The balance between adverse effects (costs) and benefits has been particularly difficult to determine with cytotoxic drugs. An approach to this problem using medical audit is described. It has been found to be a reliable method which has demonstrated a highly significant correlation between achievement of objective regression and acquisition of benefit. The method is now undergoing corroboration by a prospective study.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/S0959-8049(05)80162-5</identifier><identifier>PMID: 7679582</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic Agents - therapeutic use ; Cost-Benefit Analysis ; Humans ; Medical Audit ; Neoplasm Staging ; Neoplasms - drug therapy ; Neoplasms - economics ; Neoplasms - pathology ; Palliative Care - economics ; Quality of Life</subject><ispartof>European journal of cancer (1990), 1993, Vol.29 (4), p.604-605</ispartof><rights>1993 Pergamon Press Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-f13a15239cbe87a9dc9dea67cfa1902ab421434fc768e7e72d4bab911cf9d4983</citedby><cites>FETCH-LOGICAL-c360t-f13a15239cbe87a9dc9dea67cfa1902ab421434fc768e7e72d4bab911cf9d4983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804905801625$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,4009,27902,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7679582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rubens, R.D.</creatorcontrib><title>Cost effectiveness in the treatment of advanced solid tumours</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>When the treatment of advanced cancer is palliative in intent, evaluation of quality of life is of paramount importance in judging the effectiveness of treatment. The balance between adverse effects (costs) and benefits has been particularly difficult to determine with cytotoxic drugs. An approach to this problem using medical audit is described. It has been found to be a reliable method which has demonstrated a highly significant correlation between achievement of objective regression and acquisition of benefit. The method is now undergoing corroboration by a prospective study.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cost-Benefit Analysis</subject><subject>Humans</subject><subject>Medical Audit</subject><subject>Neoplasm Staging</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - economics</subject><subject>Neoplasms - pathology</subject><subject>Palliative Care - economics</subject><subject>Quality of Life</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEUhYMotVZ_QmFWoovRZCaZJAsRKb6g4EJdh0xyg5F51CRT8N87fdCtqwv3nHMP90NoTvANwaS6fceSyVxgKq8wuxbjqsjZEZoSwWWOBSuO0fRgOUVnMX5jjLmgeIImvOKSiWKK7hZ9TBk4Byb5NXQQY-a7LH1BlgLo1EKXst5l2q51Z8BmsW-8zdLQ9kOI5-jE6SbCxX7O0OfT48fiJV--Pb8uHpa5KSucckdKTVhRSlOD4FpaIy3oihunicSFrmlBaEmd4ZUADrywtNa1JMQ4aakU5Qxd7u6uQv8zQEyq9dFA0-gO-iEqzhhnnNPRyHZGE_oYAzi1Cr7V4VcRrDbY1Bab2jBRmKktNsXG3HxfMNQt2ENqz2nU73c6jF-uPQQVjYcNEB9Gcsr2_p-GP5hdfRk</recordid><startdate>1993</startdate><enddate>1993</enddate><creator>Rubens, R.D.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1993</creationdate><title>Cost effectiveness in the treatment of advanced solid tumours</title><author>Rubens, R.D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-f13a15239cbe87a9dc9dea67cfa1902ab421434fc768e7e72d4bab911cf9d4983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cost-Benefit Analysis</topic><topic>Humans</topic><topic>Medical Audit</topic><topic>Neoplasm Staging</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - economics</topic><topic>Neoplasms - pathology</topic><topic>Palliative Care - economics</topic><topic>Quality of Life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rubens, R.D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rubens, R.D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost effectiveness in the treatment of advanced solid tumours</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>1993</date><risdate>1993</risdate><volume>29</volume><issue>4</issue><spage>604</spage><epage>605</epage><pages>604-605</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>When the treatment of advanced cancer is palliative in intent, evaluation of quality of life is of paramount importance in judging the effectiveness of treatment. The balance between adverse effects (costs) and benefits has been particularly difficult to determine with cytotoxic drugs. An approach to this problem using medical audit is described. It has been found to be a reliable method which has demonstrated a highly significant correlation between achievement of objective regression and acquisition of benefit. The method is now undergoing corroboration by a prospective study.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>7679582</pmid><doi>10.1016/S0959-8049(05)80162-5</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 1993, Vol.29 (4), p.604-605 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75575774 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antineoplastic Agents - therapeutic use Cost-Benefit Analysis Humans Medical Audit Neoplasm Staging Neoplasms - drug therapy Neoplasms - economics Neoplasms - pathology Palliative Care - economics Quality of Life |
| title | Cost effectiveness in the treatment of advanced solid tumours |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T12%3A30%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20effectiveness%20in%20the%20treatment%20of%20advanced%20solid%20tumours&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Rubens,%20R.D.&rft.date=1993&rft.volume=29&rft.issue=4&rft.spage=604&rft.epage=605&rft.pages=604-605&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/S0959-8049(05)80162-5&rft_dat=%3Cproquest_cross%3E75575774%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75575774&rft_id=info:pmid/7679582&rft_els_id=S0959804905801625&rfr_iscdi=true |